Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer
NSCLC, Stage III
Nsclc

Interventions: Drug: Durvalumab
Device: AVENIO ctDNA Surveillance Kit
Drug: Carboplatin
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Cisplatin
Drug: Tremelimumab

First Posted Date: 2020-10-14

Last Posted Date: 2024-04-17

Lead Sponsor: Maximilian Diehn

Target Recruit Count: 48

Registration Number: NCT04585490

Locations: 🇺🇸
Stanford University, Stanford, California, United States

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial

Phase 2

Active, not recruiting

Conditions: Stage IIA1 Cervical Cancer FIGO 2018
Stage IIIB Cervical Cancer FIGO 2018
Stage IVA Cervical Cancer FIGO 2018
Stage II Cervical Cancer FIGO 2018
Stage IIIA Cervical Cancer FIGO 2018
Stage IB3 Cervical Cancer FIGO 2018
Stage IIA2 Cervical Cancer FIGO 2018
Stage IIB Cervical Cancer FIGO 2018
Stage III Cervical Cancer FIGO 2018
Stage IIIC2 Cervical Cancer FIGO 2018

Interventions: Drug: Cisplatin
Biological: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
Radiation: Radiation Therapy

First Posted Date: 2020-10-08

Last Posted Date: 2024-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT04580771

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)

Phase 3

Recruiting

Conditions: Bladder Cancer
Bladder Urothelial Carcinoma

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2020-10-05

Last Posted Date: 2024-03-12

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 14

Registration Number: NCT04574960

Locations: 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

Phase 2

Active, not recruiting

Conditions: Extensive-stage Small Cell Lung Cancer

Interventions: Drug: SHR1316
Drug: Carboplatin
Drug: Etoposide
Radiation: Radiation therapy
Drug: Cisplatin

First Posted Date: 2020-09-24

Last Posted Date: 2024-07-03

Lead Sponsor: Shandong Cancer Hospital and Institute

Target Recruit Count: 67

Registration Number: NCT04562337

Locations: 🇨🇳
Shandong Cancer Hospital and Institute, Jinan, Shandong, China

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer

Phase 2

Recruiting

Conditions: Stage II Gallbladder Cancer AJCC v8
Stage III Gallbladder Cancer AJCC v8
Stage IIIA Gallbladder Cancer AJCC v8
Stage IIIB Gallbladder Cancer AJCC v8
Stage IIB Gallbladder Cancer AJCC v8
Stage IIA Gallbladder Cancer AJCC v8

Interventions: Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Procedure: Lymphadenectomy
Procedure: Partial Hepatectomy

First Posted Date: 2020-09-22

Last Posted Date: 2024-11-05

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 186

Registration Number: NCT04559139

Locations: 🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸
NYU Langone Hospital - Long Island, Mineola, New York, United States
🇺🇸
Roper Hospital, Charleston, South Carolina, United States

and more 364 locations

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: PD-1 antibody
Drug: Gemcitabine
Drug: Cisplatin
Radiation: IMRT

First Posted Date: 2020-09-21

Last Posted Date: 2024-05-01

Lead Sponsor: Jiangxi Provincial Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT04557020

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Suizhou Central Hospital, Suizhou, Hubei, China
🇨🇳
Ganzhou Cancer Hospital, Ganzhou, Jiangxi, China

and more 4 locations

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

Phase 1

Completed

Conditions: Cervical Cancer

Interventions: Drug: M7824
Drug: Carboplatin
Drug: Paclitaxel
Radiation: Radiotherapy
Drug: Bevacizumab
Drug: Cisplatin

First Posted Date: 2020-09-16

Last Posted Date: 2024-03-08

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 25

Registration Number: NCT04551950

Locations: 🇺🇸
Stanford Health Care Hospital & Clinics, Stanford, California, United States
🇪🇸
Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia, Barcelona, Spain
🇯🇵
Osaka International Cancer Institute, Osaka-shi, Japan

and more 10 locations

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Phase 2

Completed

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: Sintilimab
Drug: Nab paclitaxel
Drug: Cisplatin

First Posted Date: 2020-09-14

Last Posted Date: 2023-02-15

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 50

Registration Number: NCT04548440

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Prospective Study Comparing Two Radiotherapy Dose/Fraction and Omitting CTVs of the Primary Tumor in Limited SCLC

Phase 2

Recruiting

Conditions: Small Cell Lung Cancer Limited Stage

Interventions: Radiation: Hyperfractionated radiotherapy
Radiation: Hypofractionated radiotherapy
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2020-09-10

Last Posted Date: 2020-09-10

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 300

Registration Number: NCT04543890

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

Phase 2

Completed

Conditions: Locally Advanced Laryngeal Squamous Cell Carcinoma
Locally Advanced Oral Cavity Squamous Cell Carcinoma
Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IVA Lip and Oral Cavity Cancer AJCC v8
Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Stage III Laryngeal Cancer AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8

Interventions: Drug: Cisplatin
Other: Hearing Handicap Inventory for Adults - Screening
Radiation: Radiation Therapy
Drug: Sodium Thiosulfate

First Posted Date: 2020-09-09

Last Posted Date: 2024-06-28

Lead Sponsor: Hyunseok Kang, MD

Target Recruit Count: 16

Registration Number: NCT04541355

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy